Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Best 7 Multi-CDN Providers in 2026

Multi-CDN has moved from backup plan to core delivery architecture. This guide ranks the 7 best Multi-CDN providers of 2026, led by IO River, and breaks down steering, behavioral consistency, observability, and governance factors that determine real resilience.
The team of Treeview, one of the leading AR and VR comapnies, wearing virtual reality glasses

25 VR and Augmented Reality Development Companies in 2026

Explore the top 25 best virtual reality (VR) and augmented reality (AR) development companies in the world

The Best Virtual and Augmented Reality Gaming Companies in 2026

Immersive gaming is thriving in 2025, and the most exciting players aren’t just the biggest names. From enterprise-focused XR pioneers like Treeview to story-driven hits by Polyarc and the indie innovation of Fast Travel Games, these 15 standout VR/AR studios prove that the future of gaming is both deeply personal and wildly creative.

Best 5 Israeli VCs Active in MedTech and Digital Health

Compare the best tech marketing agencies in 2026 for PR, SEO, ABM, and demand generation. Find the right fit for your SaaS or B2B tech brand.
Top Sustainable Packaging Companies 2026

Top Sustainable Packaging Companies 2026

Find the best sustainable packaging companies of 2026. From seaweed to molded fiber, compare materials, formats, and what actually works.
Top Defense Tech Startups Building the Next Generation of Military Technology

Top Defense Tech Startups Building the Next Generation of Military Technology

Anduril, Saronic, Helsing, and more: a close look at the defense tech startups building the next generation of military technology.
Best Tech Marketing Agencies in 2026

Best Tech Marketing Agencies in 2026

Compare the best tech marketing agencies in 2026 for PR, SEO, ABM, and demand generation. Find the right fit for your SaaS or B2B tech brand.
Read full story

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
16 Robotics Unicorns in 2026

16 Robotics Unicorns in 2026

Meet the 16 private robotics companies valued at $1B+ in 2026, from humanoid robots to defense autonomy and warehouse systems.
Healthtech Unicorns to Consider in 2026

Healthtech Unicorns to Consider in 2026

The healthtech unicorns worth watching in 2026 are tied to real care needs. Here are the private companies investors still take seriously.
10 Biotech Unicorn Startups to Watch in 2026

10 Biotech Unicorn Startups to Watch in 2026

Meet the private biotech companies valued at $1 billion or more in 2026 and find out what still makes them worth watching.
10 Insurtech Unicorn Companies to Watch in 2026

10 Insurtech Unicorn Companies to Watch in 2026

Discover the 10 insurtech unicorn companies shaping private insurance in 2026, from cyber specialists to embedded platforms.
14 Edtech Unicorns to Consider in 2026

14 Edtech Unicorns to Consider in 2026

Which edtech companies are still worth watching in 2026? We break down 14 private unicorns across training, language, and career tech.
Fintech Unicorns Around the World to Watch in 2026

Fintech Unicorns Around the World to Watch in 2026

Stripe, Revolut, Klarna, Ramp, and more. A clear look at the private fintech unicorns still worth watching in 2026.
Cybersecurity Unicorns Around the World to Watch in 2026

Cybersecurity Unicorns Around the World to Watch in 2026

The top private cybersecurity companies worth watching in 2026, from data security to supply chain protection. Valuations, funding, and what they actually do.
Read full story

Explore our collection of top interviews

Dive into our thoughtfully curated selection of insightful and impactful interviews with leaders and innovators in their fields.
Maisa CEO David Villalón

AI Costs Aren't the Problem. Enterprise AI Architecture Is, Says Maisa CEO David Villalón

Maisa CEO David Villalón explains why enterprise AI costs stem from poor architecture, not model pricing, and how multi-model systems fix it.
Carl Livie is Co-Founder and Chief Executive Officer of JustPlay

Inside JustPlay’s Vision for the Next Generation of Reward Ecosystems

JustPlay CEO Carl Livie explains how rewarded gaming can create sustainable value for players through a fully integrated ecosystem.
Encube

Interview with Hugo Nordell, CEO of Encube: Rethinking hardware manufacturing workflows

Hugo Nordell of Encube on why AI-powered hardware development tools are now essential for European manufacturers facing talent gaps and supply chain shifts.
Communities, Not Studios: Victor Folmann on Gaming’s New Power Players

Communities, Not Studios: Victor Folmann on Gaming’s New Power Players

Victor Folmann on why gaming communities, not studios, will shape the next generation of games and how Chosen is betting on that.
Interview: Zakhar Azatian, CEO & Founder, BeHard

Interview: Zakhar Azatian, CEO & Founder, BeHard

Zakhar Azatian built BeHard to 1M users and $490K MRR with no outside funding. Here's the growth system behind it.
Will Weise

A Breakthrough Bongo Antelope Birth Shows How Reproductive Technology Could Help Stop Extinction

Critically endangered Bongo antelope born to Eland surrogate in Texas breakthrough. Dr. Will Weise explains how reproductive tech fights extinction.

Shaping Fintech’s Next Chapter: An Interview with Oleg Seitov, Head of Finance at xpate

xpate's Head of Finance Oleg Seitov shares insights on balancing fintech innovation with discipline, AI automation, and sustainable growth strategies.
Read full story

Discover our top blog articles

Explore our carefully curated selection of engaging and informative blog articles on a variety of topics.
The Best 10 PR Agencies in Europe 2027

The Best 10 PR Agencies in Europe 2027

Discover the 10 best PR agencies in Europe for 2027. Compare their specialties, international reach, services, and proven client results.
Best PR agencies for Series A, B and C SaaS companies

Best PR agencies for Series A, B and C SaaS companies

Explore 12 PR agencies for Series A, B and C SaaS companies. Compare industry expertise, funding campaign experience and media relations services.

Aircraft Management Costs Explained: Crew, Maintenance, Hangar, and Operations

Private aircraft ownership costs go far beyond the purchase price. This guide breaks down crew, maintenance, hangar, fuel, and insurance expenses, and explains how understanding fixed versus variable costs helps owners budget accurately and avoid surprises.

Best Sovereign Cloud Providers in Europe

Compare the 10 best sovereign cloud providers in Europe for 2026, including Ilkari, OVHcloud, Scaleway, IONOS, AWS, Microsoft and more.
Best Sovereign Cloud Providers in Latin America

Best Sovereign Cloud Providers in Latin America

Compare 10 leading sovereign cloud providers in Latin America, including regional, government and global options for regulated workloads.

Three Reasons to Have Digital Signage

Digital signage gives businesses a flexible alternative to printed signs, with content that updates instantly and engages more effectively. This guide covers three reasons to make the switch, from stronger communication and fresher content to a more polished customer experience.

The Best Virtual and Augmented Reality Gaming Companies in 2026

Immersive gaming is thriving in 2025, and the most exciting players aren’t just the biggest names. From enterprise-focused XR pioneers like Treeview to story-driven hits by Polyarc and the indie innovation of Fast Travel Games, these 15 standout VR/AR studios prove that the future of gaming is both deeply personal and wildly creative.
Read full story

Nervonik Closes $52.5M Series B for Chronic Pain Device

Key Points
  • Nervonik closed a $52.5 million Series B led by Amzak Health, with Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital participating.
  • The Los Angeles company is developing a peripheral nerve stimulation system that combines electrical stimulation with real-time nerve feedback for chronic pain treatment.
  • Nervonik has completed a first-in-human clinical trial and will use the funding to advance clinical programs and prepare for commercialization.
April 27, 2026
Nervonik Closes $52.5M Series B for Chronic Pain Device
Credits: Bioscience Image Library / Unsplash

Funding details

Nervonik, a Los Angeles medical device company developing a peripheral nerve stimulation system for chronic pain, has closed a $52.5 million Series B financing. The round was oversubscribed, according to the company. Aydin Babakhani, who founded Nervonik and serves as its CEO, has built the company around a specific idea: that what makes nerve stimulation therapy fail is not the stimulation itself, but the absence of feedback from the body.

Peripheral nerve stimulation works by placing small electrodes near nerves outside the brain and spinal cord. Those electrodes deliver electrical pulses that interrupt pain signals before they reach the brain. It is a well-established approach, but it has a persistent weakness. For patients who cannot tolerate long-term medication, or whose medications have stopped working, it offers a real alternative. The global market for peripheral nerve stimulators was valued at $1.25 billion in 2025 and is projected to reach $2.18 billion by 2035, as demand grows for pain therapies that do not rely on opioids or invasive surgery.

The Series B was led by Amzak Health. Additional participants include Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital.

Why Current PNS Devices Operate Without Feedback

Most peripheral nerve stimulation systems in use today deliver electrical pulses with no way to measure what is actually happening inside the body. The device cannot confirm whether it is reaching the right nerve, whether the lead has moved out of position, or whether the stimulation is producing any meaningful biological effect. Clinicians programming these systems depend heavily on what patients report, which varies from person to person and visit to visit.

Nervonik is building its system around a different approach. Rather than delivering stimulation blindly, its platform records electrical signals from the nerve in real time, including what are known as evoked compound action potentials. These are measurable responses that indicate a nerve has actually been activated. By capturing this kind of data, the system can help confirm that therapy is working as intended and allow for more informed adjustments. Nervonik refers to this integration of stimulation and sensing as a closed-loop approach, and positions it within the broader field of bioelectronic medicine, which uses electrical signals to treat disease.

"Peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain," said Anthony Natale, MD, Partner at Amzak Health. "Aydin and the Nervonik team have developed a highly differentiated technology platform that we believe has the potential to meaningfully improve the patient experience, and they are exceptionally well-positioned to capitalize on this opportunity. We are excited to lead this financing and to support the company through its next phase of growth."

How Nervonik Plans to Use the $52.5 Million

The new capital will go toward three areas: moving clinical programs forward, building out the path to commercialization, and continuing to develop the company's sensing technology. Nervonik has already completed a first-in-human clinical trial. The Series B is meant to carry it from that early stage toward a product that could eventually reach patients.

Sensing remains the technical priority. Early data from the company's trials show successful recording of evoked compound action potentials through implantable leads, which Nervonik says supports its core hypothesis that real-time nerve feedback is achievable in a practical device. The next phase involves refining that capability and testing it across a broader patient population.

"Nervonik is building a fundamentally differentiated neuromodulation platform that integrates stimulation with advanced sensing to deliver more precise and personalized therapy," said Aydin Babakhani, CEO and Founder of Nervonik. "This financing enables us to accelerate our clinical programs, prepare for commercialization, and bring a truly intelligent, next-generation therapy to the patients who need it most."

Nervonik's Technology and Where the Company Stands

Babakhani founded Nervonik and continues to lead it as CEO and board member. The company is based in Los Angeles and works specifically on peripheral nerve stimulation, a category of neuromodulation that targets nerves in the body's limbs and tissues rather than the spinal cord or brain.

The technical foundation of the system is what Nervonik calls its trifecta technology, a patented design the company says removes the main obstacles to biosensing in peripheral nerve stimulation. One of those obstacles is physical. Existing PNS devices were not built for areas of the body that move frequently, and lead instability during activity is a known problem. Nervonik's system is designed with high-motion environments in mind. The team behind it includes engineers and clinicians with backgrounds at established medical device companies, along with a clinical advisory board covering pain management and neuromodulation.

The company has cleared two notable regulatory and clinical hurdles. It received approval to begin a first-in-human study and has since completed it, producing early data that support its sensing approach. That said, Nervonik's technology remains in development. It has not received FDA clearance or approval for commercial sale.

The Investors Behind the Round

Amzak Health led the Series B. The firm invests in medtech and biotech and describes its role as more than financial, working alongside portfolio companies through development and toward commercial milestones. The remaining participants in the round are Elevage Medical Technologies, U.S. Venture Partners, Lumira Ventures, Foothill Ventures, and Shangbay Capital.

Funding details

Subscribe to our newsletter

Subscribe

Last related articles

linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram